简介：目的总结19例输尿管肿瘤的诊治体会。方法术前19例均行B超、IVU和CT检查，选择性结合逆行性尿路造影或输尿管镜检查和活检。19例输尿管肿瘤中1例行输尿管节段切除加端端吻合术，行根治性肾、输尿管切除加膀胱袖状切除14例次，输尿管镜钬激光治疗输尿管癌2例，输尿管息肉3例。结果术前诊断准确率94．7％（18／19），术后随访5个月～7年，平均3．2年，1例输尿管节段切除术后1年复发，1例腔内手术半年发生输尿管狭窄，膀胱肿瘤发生3例，随访≥5年7例，存活3例。结论B超、IVU和逆行性尿路造影可作为输尿管肿瘤的初步诊断，CT可以帮助诊断和临床分期，输尿管镜检查可提高输尿管肿瘤诊断正确率和确定病理类型。输尿管肿瘤手术预后取决于病理分级和临床分期，腔内手术仅适合于早期低级别肿瘤。

简介：目的探讨导致子宫破裂的相关因素及预防和减少其发生的有关措施。方法回顾性分析我院2003年1月至2007年12月19例子宫破裂患者的临床资料。结果子宫破裂的发生率为1．06‰；其中完全性子宫破裂10例，不完全性子宫破裂9例；子宫破裂修补术13例，双输卵管结扎术10例，全子宫切除术6例，阴道裂伤修补术2例；孕产妇发生产后出血10例，治愈出院18例，死亡1例；新生儿窒息5例，死产3例。结论药物使用不当是子宫破裂发生的首要原因，其次为子宫瘢痕破裂和梗阻性难产。子宫修补术是子宫破裂最常见的手术方式。加强有效的预防措施，可以降低子宫破裂的发牛．改善母罂预后．

简介：

简介：

简介：对我院自1980年～1990年间收治的早期胃癌19例进行回顾分析。发现手术切除标本癌灶大小的均值与纤维胃镜下所测得的结果比较有显著差异,5年以上生存率较对照组有显著差异。作者认为提高胃癌生存率的关键是:①早发现:加强卫生知识宣教及高危人群普查;②早诊断:提高纤维胃镜及病理诊断水平;③尽早行胃癌根治术。

简介：1999-01／2004-12我们收治睾丸扭转病人19例，现将诊治情况和体会报告如下。

简介：

简介：

简介：无

简介：摘要目的回顾性分析新型冠状病毒肺炎(COVID-19)患者的临床资料，认识重症COVID-19患者的临床特征，切实指导临床实际工作。方法总结分析2020年1月28日至2020年2月12日于北京佑安医院住院治疗的确诊为COVID-19重型、危重型19名患者的临床资料，包括患者年龄、性别、病程、流行病学史、既往史、临床症状、实验室检查、肺部CT表现、治疗以及临床结局。统计学处理采用SPSS 22.0软件。结果被纳入本研究的19名患者，重型10例、危重型9例；年龄58～94岁，平均75岁；男性10人、女性9人。病程从1～14 d不等，病程中位数5 d。4人有明确的武汉居住史、13人与确诊患者有密切接触者(包括家庭聚会、共餐、同居一室等)、2人无相关的流行病学史。14人患有慢性基础病(其中高血压病11例、冠心病4例、心功能不全4例、慢阻肺3例、陈旧性前壁心梗2例、心律失常3例、心脏瓣膜病1例、糖尿病2例、慢性肾病2例等)，4例患者同时合并3种及以上基础病。首发症状主要为发热18例、咳嗽13例、呼吸困难8例。就诊时17例患者伴有淋巴细胞计数低于正常范围，11例有不同程度的肝脏功能异常，10例患者心肌酶谱异常，7名患者不同程度的肾功能损害。18名患者C-反应蛋白升高。12例接受激素治疗，4例接受丙球治疗，无创呼吸机机械通气3例，有创呼吸机协助通气7例。1例患者接受持续血液净化(continuous renal replacement therapy，CRRT)治疗，1例患者接受体外膜肺氧合(extracorporeal membrane oxygenation，ECMO)治疗；截至2020年2月17日，10例患者病情好转，4例患者仍在ICU治疗，5例患者死亡。结论老年人以及合并有慢性基础疾病患者更易发展为重型、危重型病例。淋巴细胞计数降低、C-反应蛋白水平升高、肝肾功能及心肌酶谱异常与重症化相关。激素及呼吸机治疗重症有效。

简介：当热浪开始在这个夏天里蔓延开来的时候，尤其是在午后，困乏、倦怠让你显得倍加慵懒。咖啡让精神振奋，却无法叫醒你困倦的肌肤，就从今天开始学起来，让好精神、好皮肤与你一起过个清醒好夏天。

简介：Wehavepreviouslydemonstratedtheabilityofmalariaparasitestointerferewithspecificimmuneresponses.CD4Tcellsspecifictoparasiteantigens,butnotCD4Tcellsspecifictoanirrelevantantigen,ovalbumin(OVA),aredeletedviaapoptosisduringmalariainfection.Itisofinterest,therefore,toinvestigatetheimmuneresponsesthatdevelopedfollowingvaccinationwiththe19kDacarboxylterminusofthemerozoitesurfaceprotein1(MSP119)inmicethathadpreviouslyexperiencedmalariainfection.Inthisstudy,pre-exposureofmicetoPlasmodiumyoeliielicitednativeanti-MSP119antibodyresponses,whichcouldbeboostedbyvaccinationwithrecombinantMSP119，Likewise,infectionofMSP119-primedmicewithPlasmodiumyoelii(P.yoelii)ledtoanincreaseofanti-MSP119antibodies.MSP119vaccinationofmalariapreexposedmiceorimmunizationbyinfection/cureofMSP119-primedmiceenabledthemicetosurvivechallengeinfection,withtheformergrouphavingslightlylowerparasitaemia.Thedatasuggestthatexposuretomalariainfectionprimesanaturalimmuneresponsewhichcanbeboostedbyvaccination.Thisinformationisrelevanttothedevelopmentofavaccineforuseinindividualslivinginmalaria-endemicareas.

简介：AbstractThe impact of coronavirus disease 2019 (COVID-19) on endometriosis (EM) is currently unclear. Here, we aimed to describe the potential influence of COVID-19 on the pathogenesis, clinical symptoms, and treatment of EM. The cytokine storm caused by COVID-19 may induce the occurrence and progression of EM, and immunosuppression of COVID-19 may help the ectopic endometrium escape from immune clearance. Consequently, the forced social isolation and the cancelation of non-emergency medical treatment during the COVID-19 pandemic aggravate anxiety and psychological pressure, which can aggravate the symptoms related to EM and delay routine medical services.

简介：无

简介：无

简介：AbstractBackground:To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods:This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results:A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled; 66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64] vs. 42.4% [14/33]; difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P = 0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 days vs. 12.0 days; hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060, P = 0.006), symptom of fever (median 3.0 days vs. 12.0 days; HR: 18.990, 95% CI: 5.350-67.410, P < 0.001), as well as hospitalization (median 12.5 days vs. 20.0 days; P < 0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 days vs. 14.5 days; P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions:SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.Trial registration:Chinese Clinical Trial Registry, NCT04260594, www.clinicaltrials.gov/ct2/show/NCT04260594?term= NCT04260594&draw=2&rank=1

简介：摘要由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒疾病（COVID-19）已经在全球多个国家引起大流行，该病毒传染性强、致死率高，部分变异株在病毒传播性、致病性和免疫原性等多方面发生变化。无症状感染和有症状感染的COVID-19患者在免疫特征上存在异质性；不同年龄阶段的COVID-19患者的临床表现也不尽相同。目前无治疗COVID-19的特效药物，疫情控制需依赖新型冠状病毒疫苗的接种，如核酸疫苗、灭活疫苗、病毒载体疫苗、蛋白质疫苗等。本文通过对新型冠状病毒的变异、临床表现、治疗和疫苗等方面文献的复习，展现目前相关研究的进展。

简介：摘要目的观察走罐治疗痤疮的疗效。方法用背部走罐法治疗19例痤疮患者,20天后观察疗效。结果总有效率为89.5%。结论走罐法对痤疮有明显疗效。

简介：摘要Coronavirus disease (COVID-19), the infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported on December 31, 2019. Because it has only been studied for just over three months, our understanding of this disease is still incomplete, particularly regarding its sequelae and long-term outcomes. Moreover, very little has been written about the rehabilitation needs of patients with COVID-19 after discharge from acute care. The objective of this report is to answer the question " What rehabilitation services do survivors of COVID-19 require？" The question was asked within the context of a subacute hospital delivering geriatric inpatient and outpatient rehabilitation services. Three areas relevant to rehabilitation after COVID-19 were identified. First, details of how patients may present have been summarized, including comorbidities, complications from an intensive care unit stay with or without intubation, and the effects of the virus on multiple body systems, including those pertaining to cardiac, neurological, cognitive, and mental health. Second, I have suggested procedures regarding the design of inpatient rehabilitation units for COVID-19 survivors, staffing issues, and considerations for outpatient rehabilitation. Third, guidelines for rehabilitation (physiotherapy, occupational therapy, speech-language pathology) following COVID-19 have been proposed with respect to recovery of the respiratory system as well as recovery of mobility and function. A thorough assessment and an individualized, progressive treatment plan which focuses on function, disability, and return to participation in society will help each patient to maximize their function and quality of life. Careful consideration of the rehabilitation environment will ensure that all patients recover as completely as possible.

简介：AbstractCoronavirus disease 2019 (COVID-19) is a newly emerged infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The number of COVID-19 cases is continuously increasing and no effective drugs or vaccines are currently available. Accurate and efficient diagnostic testing methods are desperately needed for the detection of SARS-CoV-2 and antiviral antibodies in infected individuals. Various assay techniques, including nucleic acid tests [eg, polymerase chain reaction (PCR), reverse transcription-PCR, real-time loop-mediated isothermal amplification, and CRISPR-Cas-based detection], serological tests [eg, immunoglobulin (Ig)A, IgM/G], imaging tests (eg, computed tomography and positron-emission tomography), and nanoparticle-based detections have been reported for COVID-19 diagnosis. This review aims to present the current diagnostic tools for SARS-CoV-2 and their performance characteristics to inform the appropriate selection of diagnostic and surveillance technologies at optimal testing times. We also describe the advantages of detection using combined nucleic acid and imaging tests, or serological testing and point-of-care diagnostics. Developing reliable protein biomarkers targeting the conserved proteins of SARS-CoV-2 rather than IgA, IgM, or IgG would be useful to manage SARS-CoV-2.